Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05655676 | 89Zr-labeled NY008 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05616468 | BGT007 Cell Treatment of Nasopharyngeal Carcinoma | unknown | Early Phase 1 | 23 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | unknown | Early Phase 1 | 19 | Shenzhen Pregene Biopharma Co., Ltd.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05651191 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | unknown | Early Phase 1 | 9 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04114370 | Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma(FACBC) | completed | Early Phase 1 | 9 | James MountzOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05638256 | 68Ga-labeled NY104 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05017610 | Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma | withdrawn | Early Phase 1 | 0 | Emory UniversityOTHER | 0 | Dec 2, 2022 | clinicaltrials |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL | withdrawn | Early Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05015972 | UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies | withdrawn | Early Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05519384 | Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia | unknown | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05622240 | 99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR) | withdrawn | Early Phase 1 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02851056 | Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | completed | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05271279 | A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors | terminated | Early Phase 1 | 2 | Beijing Boren HospitalOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05016778 | A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | unknown | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02405078 | Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | completed | Early Phase 1 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05003427 | 68Ga-FAPI-04 PET/CT for the Detection of Oral Carcinoma | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04797728 | Elacestrant in Preoperative Setting, a Window of Opportunity Study(ELIPSE) | completed | Early Phase 1 | 23 | SOLTI Breast Cancer Research GroupOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT04130152 | Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy(PROMETEO II) | completed | Early Phase 1 | 22 | SOLTI Breast Cancer Research GroupOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05589961 | Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme | unknown | Early Phase 1 | 10 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05034783 | [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients | unknown | Early Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02065609 | 89ZrTrastuzumab Breast Imaging With Positron Emission Tomography | completed | Early Phase 1 | 52 | Washington University School of MedicineOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT02072356 | Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | completed | Early Phase 1 | 290 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03858491 | Pharmacokinetic Boosting of Osimertinib(OSIBOOST) | completed | Early Phase 1 | 11 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT04776980 | Multimodality MRI and Liquid Biopsy in GBM | withdrawn | Early Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT04267900 | 99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer | completed | Early Phase 1 | 34 | Peking Union Medical College HospitalOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT00962845 | Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | completed | Early Phase 1 | 20 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT03020017 | NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery | completed | Early Phase 1 | 8 | Northwestern UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05395260 | FL- 101 Study in Non-Metastatic MIBC | withdrawn | Early Phase 1 | 0 | Flame BiosciencesINDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT04974281 | PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC | unknown | Early Phase 1 | 50 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05505812 | Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer | not yet recruiting | Early Phase 1 | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04102618 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer(AWARE-1) | terminated | Early Phase 1 | 26 | Oncolytics BiotechINDUSTRY | 1 | Aug 15, 2022 | clinicaltrials |
| NCT03655756 | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | completed | Early Phase 1 | 7 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT04019834 | Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy(RELIEF) | completed | Early Phase 1 | 21 | University of Alabama at BirminghamOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05013372 | CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | unknown | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04065555 | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | completed | Early Phase 1 | 12 | Presage BiosciencesINDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05480501 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05478343 | Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 28, 2022 | clinicaltrials |
| NCT03526185 | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | terminated | Early Phase 1 | 6 | Yale UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01781741 | Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Early Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02885272 | FDG PET Imaging in Diagnosing Patients With Glioblastoma | completed | Early Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT03982407 | 68 Ga PSMA PET/MRI for Hepatocellular Carcinoma | completed | Early Phase 1 | 5 | Ajit H. Goenka, MDOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT04996602 | Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05459441 | Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases | unknown | Early Phase 1 | 30 | Shanghai Pudong HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04288336 | Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05444322 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 18 | He HuangOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT02626130 | Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer | completed | Early Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05438797 | The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer | unknown | Early Phase 1 | 3 | Sizhen WangOTHER | 1 | Jun 30, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Dec 19, 2022source: clinicaltrials